3. Overall survival.
| Study | MSD‐HSCT | IST | Time1 | P value | ||
| N | OS (95% CI) | N | OS (95% CI) | Year | ||
| Bayever 1984 | 35 | 72% (64 to 80) | 22 | 45% (29 to 61) | 2 | 0.18 |
| Führer 1998 | 28 | 84% (NR) | 86 | 87% (NR) | 4 | 0.43 |
| Gratwohl 1981 | 19 | 47% (NR) | 13 | 69%2 (NR) | 5 | 0.563 |
1Time point of Kaplan‐Meier estimate.
2Gratwohl 1981: Two of 13 patients were eligible for MSD‐HSCT but donors were not available in the first place; the two patients died after they received a second‐line HSCT from the then again available MSD that was offered after the patients showed no response to IST.
3 The P value was not reported and we calculated the P value using Fisher's exact test.
Abbreviations: CI: confidence interval; IST: immunosuppressive therapy including ciclosporin and/or antithymocyte or antilymphocyte globulin; MSD‐HSCT: first‐line allogeneic hematopoietic stem cell transplantation from HLA‐matched sibling donor; N: number of analyzed patients; NR: not reported; OS: overall survival